Streetbeat News

ZVSA

ZyVersa Therapeutics, Inc.

https://www.zyversa.com

Industry

Biotechnology

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Open

0.59

Mkt cap

1.5M

Volume

6.1K

High

0.61

P/E Ratio

-0.07

52-wk high

8.05

Low

0.58

Div yield

N/A

52-wk low

0.58

During Friday's pre-market session, several healthcare stocks experienced significant movement. Biocept, Impel Pharmaceuticals, Senti Biosciences, ZyVersa Therapeutics, Rezolute, and Elutia saw increases in their stock prices, while Soligenix, NeuBase Therapeutics, Cyclo Therapeutics, GRI Bio, Asensus Surgical, and Palisade Bio experienced decreases.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 1:06 pm

HC Wainwright has initiated coverage on ZyVersa Therapeutics with a Buy rating and a price target of $2.5. This has led to an increase in the trading of ZyVersa shares.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 12:38 pm

HC Wainwright & Co. analyst Ed Arce has initiated coverage on ZyVersa Therapeutics (NASDAQ:ZVSA) with a Buy rating and a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

September 08, 2023 | 10:59 am

ZyVersa Therapeutics (NASDAQ:ZVSA) reported a significant increase in its Q2 losses, with EPS at $(4.84), a 4740% increase from $(0.10) YoY.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 8:17 pm

The article lists the top 5 oversold health care stocks that could potentially rise in August. The stocks mentioned are BIOLASE, Inc. (BIOL), G Medical Innovations Holdings Ltd (GMVD), Allarity Therapeutics, Inc. (ALLR), ZyVersa Therapeutics, Inc. (ZVSA), and Penumbra, Inc. (PEN). The stocks are considered oversold as their Relative Strength Index (RSI) is near or below 30.

Portfolio Pulse from Lisa Levin

August 04, 2023 | 3:12 pm

On Monday, 70 companies hit new 52-week lows. Estee Lauder Cos was the largest firm by market cap to set a new 52-week low, while 9 Meters Biopharma was the smallest. AppHarvest was the biggest loser, trading down 70.3% to reach its 52-week low, while SWK Holdings was the biggest winner, with shares trading up 0.0% after rebounding from its new 52-week low.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 7:48 pm

The article lists the stocks that gained and lost the most in Monday's mid-day session. Tupperware Brands Corporation (TUP), Vinco Ventures (BBIG), and Spark Networks (LOV) were among the top gainers, while AppHarvest (APPH), Kodiak Sciences (KOD), and BioCardia (BCDA) were among the top losers. Ryanair Holdings (RYAAY) shares fell by 8.3% after the company reported quarterly results.

Portfolio Pulse from Lisa Levin

July 24, 2023 | 6:54 pm

Shares of AMC Entertainment Holdings surged 41% in pre-market trading after a Delaware judge denied the company from converting its AMC preferred equity units into common stock. Other notable pre-market movers include ZyVersa Therapeutics, POSCO Holdings, and Akumin Inc. on the gainers' side, and Contango Ore, AppHarvest, and ViewRay on the losers' side.

Portfolio Pulse from Lisa Levin

July 24, 2023 | 12:16 pm

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) has announced the pricing of a public offering of 12,727,273 shares of common stock and warrants at $0.165 per unit, aiming to raise approximately $2.1 million. The proceeds will be used for working capital, general corporate purposes, and potentially to redeem the remaining outstanding shares of its Series A preferred stock. The closing of the offering is expected on July 26, 2023.

Portfolio Pulse from Happy Mohamed

July 24, 2023 | 12:12 pm

The article lists the stocks that have gained and lost the most in Wednesday's mid-day session. Among the gainers, Biodexa Pharmaceuticals, SMX, Carvana, and Panbela Therapeutics saw significant increases due to various reasons such as patent allowances, better-than-expected sales, and asset divestitures. Among the losers, Sono Group, Amarin Corporation, Aqua Metals, and Aptevo Therapeutics saw significant decreases due to reasons such as delisting notices, organizational restructuring, and public offerings.

Portfolio Pulse from Lisa Levin

July 19, 2023 | 5:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.